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BACKGROUND. Splenic marginal zone lymphoma (SMZL) is a well deﬁned patho-
logic entity. However, questions regarding the bone marrow inﬁltration rate, the
minimal diagnostic data set, and therapy remain unanswered.
METHODS. Clinical-pathologic features and outcomes of 57 consecutive patients
who had splenomegaly with no clinically signiﬁcant lymphadenomegaly and who
were diagnosed with SMZL with or without () villous lymphocytes (VL) were
reviewed.
RESULTS. SMVL  VL occurred mostly in elderly males (median age, 62 years  10
years; male-to-female ratio, (1.85). Anemia was recorded in 49% of patients, and
30% of patients had moderate thrombocytopenia. Leukocytosis and leukopenia
were found in 33% and 14% of patients, respectively, and typical VL were found in
84% of patients. Serology for hepatitis C virus infection was positive in 16% of
patients, and a small monoclonal component was detected in 36% of patients. The
bone marrow was inﬁltrated with an intrasinusoidal component in all patients.
Thirteen patients were monitored using a watch-and-see policy, and they re-
mained alive 1–5 years after diagnosis. Overall, 21 patients (36%) underwent
splenectomy; and, in all patients, the diagnosis of SMZL was conﬁrmed histolog-
ically in the surgical specimens. Twenty-ﬁve patients received single-agent ther-
apy, which included either alkylators or pentostatine, and they achieved an overall
response rate (ORR) of 65% and 87%, respectively: Polychemotherapy was admin-
istered to 6 patients (ORR, 83%). The median survival for all patients in the series
was not reached, and it is expected that 70% of patients will be alive at 5 years.
CONCLUSIONS. Up to 20% of patients who had SMZL  VL could be monitored
using a watch-and-wait policy. The bone marrow intrasinusoidal inﬁltration pat-
tern may be a valuable diagnostic hallmark, thus obviating diagnostic splenec-
tomy. The issues regarding prognostic stratiﬁcation and the best therapeutic strat-
egy need to be addressed in properly designed, prospective trials. Cancer 2004;
101:2050–7. © 2004 American Cancer Society.
KEYWORDS: splenic marginal zone lymphoma, splenic lymphoma with villous lym-
phocytes, splenectomy, intrasinusoidal, bone marrow biopsy.
Splenic marginal zone lymphoma (SMZL) with or without ()villous lymphocytes (VL) is a recently recognized, chronic B-cell
lymphoproliferative disorder1 that is listed as a distinct pathologic
entity in the World Health Organization (WHO) classiﬁcation system.2
SMZL VL is infrequent, accounting for only 8% of all lymphomas,
and it occurs primarily in the elderly (median age at onset, 68 years)
with a male-to-female ratio of 1.0:1.8.3
When a leukemic component is present ( 10% of lymphocytes
show a villous morphology), the diagnosis is splenic lymphoma with
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villous lymphocytes (SLVL).4,5 These leukemic lym-
phoid cells display thin and unevenly distributed,
short cytoplasmic projections. The immunopheno-
type of lymphomatous cells comprises surface immu-
noglobulin M (sIgM), and sIgD expression; CD19,
CD20, CD79a positivity, and a lack of CD5, CD10,
CD23, CD43, and nuclear cyclin D1.2 In some patients,
an atypical phenotype can be observed that expresses
CD5, CD23, or cyclin D1.6 In such cases, FMC7 expres-
sion can be useful in differentiating SMZL  VL from
chronic lymphocytic leukemia.
It has been reported that trisomy 3 is present in
 20% of tumors,7 and up to 40% show a deletion or
translocation of the long arm of chromosome 7 (7q21–
32).8 This disease involves the spleen, the bone mar-
row,9,10 often the blood, but rarely other tissues, with-
out signiﬁcant lymphadenomegaly or hepatomegaly.4
SMZL and SLVL are indistinguishable histologically, in
both the spleen and the bone marrow, and it is be-
lieved that they are different phases of the same pro-
cess.11
The most common clinical ﬁndings on diagnosis,
in addition to splenomegaly, are related to a mild
degree of anemia, often secondary to hypersplenism.3
Monoclonal gammopathy, mostly  2 g/dL and of the
IgM type, is detected in up to one-third of patients.
Signs of hepatitis C virus (HCV) infection and/or of
HCV-related chronic hepatic disease are present in
 20% of patients.12
Diagnosis historically has been based on the his-
tologic examination of surgically removed spleens or
on the morphologic and immunophenotypic features
of the leukemic cells. Splenectomy is regarded as the
best therapeutic choice for patients who become
symptomatic and/or develop cytopenia.13 However,
only a few series with  50 patients have been pub-
lished.4,11,13–17
Currently, the minimal diagnostic data set, the
bone marrow inﬁltration rate, the factors that affect
prognosis, and the best therapeutic approach remain
matters of debate. Herein, we present our experience




Between October, 1988 and July, 2001, 57 patients
were diagnosed with SMZL  VL at the Division of
Hematology, University of Palermo, and at the Divi-
sion of Hematology, University of Verona. The follow-
ing data were gathered at the time of diagnosis: de-
mographic data, clinical symptoms, blood counts at
presentation, clinically detectable splenomegaly, hep-
atomegaly, lymphadenopathy, the presence of a se-
rum monoclonal component, anti-HCV antibodies,
patterns of bone marrow inﬁltration, treatment, type
of response, response duration, and causes of death.
Diagnoses were made based on histologic exami-
nation of bone marrow and/or spleen integrated with
immunophenotypic and cytologic data. Four diagnos-
tic hallmarks were considered for diagnosis in patients
with splenomegaly who were without clinically signif-
icant peripheral lymphoadenomegaly: 1) the presence
of clonal (light chain-restricted), circulating CD19/
CD20-positive (CD19/CD20) B lymphocytes that
were negative for CD5, CD10, CD23, and CD25; 2)
 10% typical villous lymphocytes in the peripheral
blood; 3) intrasinusoidal bone marrow inﬁltration pat-
tern by B-mature lymphocytes; and 4) a diagnosis of
SMZL on surgically removed spleen.
The diagnosis was considered deﬁnite when un-
ambiguous spleen histology and/or a leukemic clone
that showed typical immunophenotype and villous
morphology was present. When these two major diag-
nostic criteria were lacking, but an intrasinusoidal
bone marrow inﬁltration pattern and/or a peripheral
B-cell clone that was negative for CD5, CD10, and
CD23 and that did not show villous morphology was
present, then the diagnosis was considered probable.
Patients with histologically proven nodal marginal
zone lymphoma, even if they showed some degree of
splenomegaly, were not included.
Pathology
Parafﬁn sections from bone marrow trephine biopsies
were available in all patients and also in spleen spec-
imens from the 21 patients who underwent splenec-
tomy. Histopathologic evaluation was performed us-
ing hematoxylin and eosin, periodic acid-Schiff,
Giemsa, and Gomori stains. Immunostainings were
performed with the streptavidin-biotin peroxidase
complex, using the following antibodies: CD5, CD20,
CD23, CD10, and CD43. Histologic data were reviewed
by two of the authors (V.F. and F.M.) and were classi-
ﬁed according to WHO criteria.
Immunophenotyping
Immunophenotyping and morphologic evaluations
were performed at the referral centers on peripheral
blood (PB) samples that were taken at the time of
diagnosis and before any treatment started. Brieﬂy, PB
samples were collected in tubes containing K3 ethyl-
enediamine tetraacetic acid as an anticoagulant. All
samples were stained using a direct immunoﬂuores-
cence stain-and-then-lyse technique with the follow-
ing battery of phycoerythrin (PE) or ﬂuorescein iso-
thiocyanate (FITC)-conjugated monoclonal antibodies:
CD19, CD20, CD22, CD23, CD5, CD10, CD103, CD11c,
Splenic Marginal Zone Lymphoma/Iannitto et al. 2051
CD25, sIg, and sIg (Becton Dickinson). Acquisition
and analysis were performed using CellQuest software
on a FACScan ﬂow cytometer (Becton Dickinson).
B lymphocytes were identiﬁed according to their
side scatter low intensity (SSClo/int)/CD19 distribu-
tion, and their percentage was calculated after exclud-
ing cell debris and platelets according to conventional
procedures. The common, albeit nonspeciﬁc, SMZL
immunophenotypic pattern, according to the WHO
criteria, is compared with that of other small B-cell
lymphomas in Table 1.
Treatment
Treatment was administered according to local policy
and was at the discretion of the physician in charge.
Response Criteria
Regrettably, clinical characteristics, the frequent use
of splenectomy as a diagnostic tool, and the unsatis-
factory response to the systemic therapy made it dif-
ﬁcult to use classic response criteria. We used the
following criteria to score and record clinical re-
sponses. A complete remission (CR) was deﬁned as
the disappearance of all signs and symptoms of the
disease. A good hematologic response (GHR) was
deﬁned as a reduction of the bone marrow lympho-
matous inﬁltration  50% in the absence of any kind
of cytopenia and splenomegaly. A minor hemato-
logic response (MHR) was deﬁned when at least 1 of
the following criteria was fulﬁlled: 1) recovery from
anemia or an increase  2 g/dL in the hemoglobin
level; 2) recovery from thrombocytopenia or an in-
crease  50% in the platelet count; 3) a reduction
 50% in lymphocytosis; 4) recovery from spleno-
megaly or a decrease  50% in spleen size; and 5) a
reduction  50% in the bone marrow lymphoid
inﬁltrate.
Statistics
All data were analyzed with the SPSS software package
(Scientiﬁc Software for Professional Statistics, Chi-
cago, IL). Overall survival was calculated as the time
elapsing from diagnosis either to death or to last fol-
low-up. Event-free survival was calculated as the time
from the onset of therapy to the date of treatment after
the institution of the initial watch-and-see policy, the
development of recurrent or progressive disease,
death from any causes, or loss of follow-up. Follow-up
evaluation of patients who did not experience any of
the above indicated events was recorded at the date of




Clinical and hematologic ﬁndings at the time of diag-
nosis are shown in Table 2. In this series, the disease
TABLE 2
Hematologic and Physical Features on Diagnosis in 57 Patients
with Splenic Marginal Zone Lymphoma
Characteristic No. of patients (%)
Male:female ratio 37:20
Age (yrs)
Median 62  10
Range 35–83
Hemoglobin  11 g/dL 28 (49)
Leukocytes  4000/L 10 (17)
Platelets  100.000/L 17 (30)
Leukocytes  30.000/L 20 (33)
Lymphocytes  5000/L 25 (55)
Villous lymphocytes  10% 48 (80)
HCV serology positivea 7 (17)
Monoclonal componentb 18 (36)
Splenomegaly 52 (91)
Splenomegaly  7 cm 40 (70)
Hepatomegaly 9 (16)
Abdominal lymph nodes 20 (35)
Superﬁcial lymph nodes 9 (16)
HCV: hepatitis C virus.
aSerology was unavailable for 15 patients.
bImmunoﬁxation was not performed for eight patients.
TABLE 1
Immunophenotypical Analysis and Differentiation
Immunophenotype IgM IgD CD5 CD19 CD20 CD23 CD43 CD79a Cyclin D1
SMZL/SLVL         
HCL         
CLL/SLL         
PLL         
MCL         
IgM: immunoglobulin M; SMZL/SLVL: splenic marginal zone lymphoma/splenic lymphoma with villous lymphocytes; : positive; : negative; : weakly positive; HCL: hairy cell leukemia; CLL/SLL: chronic
lymphocytic leukemia/small lymphocytic lymphoma; PLL: prolymphocytic leukemia; MCL: mantle cell lymphoma.
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occurred mostly in elderly males (median age, 62 years
 10 years; male-to-female ratio, 1.85). All but 6 pa-
tients showed splenomegaly that was appreciated  7
cm below the left costal margin in 40 patients (70%).
Hepatomegaly was recorded in 14 patients (24%).
Nine patients (16%) also had small (about 1 cm) su-
perﬁcial or abdominal lymph nodes.
Laboratory Characteristics
A slight-to-moderate anemia (hemoglobin  11 g/dL)
was recorded in 49% of patients. Seventeen patients
(30%) showed moderate thrombocytopenia (
100,000/L), which was severe in only 1 patient (
20,000/L). Leukocytosis (leukocyte count  10,000/
L) and leukopenia (leukocyte count 4000/L) were
found in 33% and 17% of patients, respectively. Only 1
patient had  500 neutrophils/mm3. Morphologically
typical villous lymphocytes were found in 84% of pa-
tients, irrespective of the leukocyte count (Fig. 1). A
monoclonal component was detected in 36% of patients,
and two-thirds were of the IgM type. Seventeen percent
of the 42 patients screened were anti-HCV positive. A
bone marrow trephine biopsy was performed in all pa-
tients. The bone marrow showed a slight-to-moderate
lymphoid inﬁltration in all patients. An intrasinusoidal
component was detected consistently, and the inﬁltrate
was exclusively intrasinusoidal in 34% of patients (Fig.
2). In the remaining patients, the intrasinusoidal pattern
FIGURE 2. Circulating villous lymphocytes: Neoplastic lympho-
cytes are characterized by the presence of short polar projections
(Giemsa stain; original magniﬁcation,  1000).
FIGURE 1. Bone marrow intrasinusoidal inﬁltration: Anti-CD20
immunostaining highlights the lymphomatous cells, which are
lodged inside the bone marrow sinusoids (avidin-biotin complex
method; CD20 immunostain; original magniﬁcation,  250).
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was observed along with a prevalent nodular or intersti-
tial component. Data regarding the bone marrow inﬁl-
tration patterns are reported in Table 3.
Response to Therapy
Thirteen patients were monitored on a watch-and-see
policy until the disease progressed and remain alive
1–5 years after diagnosis. The remaining patients re-
ceived  1 lines of treatment (range, 1–4 treatments),
including alkylating, purine analogues, splenic irradi-
ation, or splenectomy. Overall, 21 patients (36%) un-
derwent splenectomy; and, in all patients, the diagno-
sis of SMZL was conﬁrmed histologically in the
surgical specimens. Nine of 12 patients who under-
went splenectomy at the time of diagnosis, all of
whom showed a bone marrow intrasinusoidal inﬁltra-
tion pattern, were classiﬁed with SMZL, because they
had no obvious leukemic component.
After splenectomy, nearly all the patients obtained
a MHR or GHR. A clinical response (CR) lasting from 6
months to 7 years (median, 4 years) was observed
irrespective of whether splenectomy was the ﬁrst line
of treatment or a salvage procedure. Eight out of the
13 patients who underwent bone marrow follow-up
after splenectomy showed worsening of both the de-
gree and the pattern of bone marrow inﬁltration.
Splenic irradiation was employed in two patients,
who both improved clinically. The overall response
rate (ORR) was 55%. Data on response to ﬁrst-line,
systemic therapy are reported on Table 4.
Six out of 8 patients (75%) who were treated with
pentostatine obtained a clinical response (5 MHRs
and 1 CR). In addition, with the inclusion of 6 patients
who received pentostatine as salvage therapy, the ORR
rate was 78% (8 MHRs and 3 CRs).
Overall, 17 patients received ﬁrst-line therapy
with alkylators, and 6 patients received combination
chemotherapy. Only one patient obtained a CR, and
the ORR for monochemotherapy and polychemo-
therapy was of 65% and 83%, respectively.
Outcomes
The median survival for the entire series was not
reached, and 70% of patients are expected to be alive
at 5 years (Fig. 3). Fourteen patients (24%) died, in-
cluding 12 deaths from lymphoma progression and 2
deaths from a secondary malignancy. Seven of 10 lym-
phoma-related deaths occurred within 36 months of
diagnosis.
DISCUSSION
The results of our study, which was performed on 57
patients, conﬁrm that SMZL  VL is a disease of the
elderly with a slight male prevalence. Patients mostly
are asymptomatic, and the most frequent symptoms
are related to mild anemia. We found that bone mar-
row also is involved constantly in patients who do not
show villous lymphocytes in PB. The lymphoid inﬁl-
trate is often very ﬁne and is conﬁned to the bone
marrow sinusoids in more than one-third of patients.
It is known that the intrasinusoidal inﬁltration
pattern occurs in rare lymphomas of both T-cell lin-
eage (large granular cell leukemia and hepatosplenic
T-cell lymphoma) and B-cell lineage (intravascular
large B-cell lymphoma).10 However, in cases in which
the inﬁltrate is made up of small B lymphocytes, it is
characteristic of SMZL. In all 21 patients who were
diagnosed with probable SMZL in the current study,
the diagnosis was conﬁrmed after examination of
splenectomy specimens. Our data suggest that the
bone marrow intrasinusoidal inﬁltration pattern may
be a valuable diagnostic hallmark, which, coupled
with careful morphologic and immunophenotypic ex-
amination of PB, can lead conﬁdently to the correct
diagnosis.
Another interesting ﬁnding in our series, which
also was reported recently in the literature,12 was the
high HCV prevalence rate, and impressive results have
been described with interferon therapy in HCV-posi-
tive patients who have SLVL.18 Hermine et al. reported
that antiviral therapy can result in a CR of HCV infec-
TABLE 3
Bone Marrow Inﬁltration Data
Pattern No. of patients (%)
Intrasinusoidal 57 (100)
Intrasinusoidal and nodular 14 (25)
Intrasinusoidal, interstitial, and nodular 8 (14)
Intrasinusoidal and interstitial 3 (5)
Inﬁltration  30% 22 (60)
TABLE 4







Watch and see 13 — — — —
Splenectomy 12 — 8 3 91
Splenic irradiation 2 — — 2 100
Monochemotherapy
Chlorambucil 17 — 2 9 65
Pentostatine 8 1 — 6 87
Polychemotherapya 6 1 2 2 83
CR: complete response; GHR: good hematologic response; MHR: minor hematologic response; ORR:
overall response rate.
a Only one patient received combined chemotherapy without anthracyclines.
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tion and SLVL in patients with coexisting cryoglobu-
linemia. Of the nine treated patients, seven patients
achieved a CR after the loss of detectable HCV RNA.
The other two patients obtained a CR and a partial
remission after the addition of ribavirine and the loss
of detectable HCV RNA. Thus, these results, if con-
ﬁrmed, stress the importance of prospective trials ex-
amining the response of HCV-positive patients with
SMZL to the association of ribavirine and pegylated
interferon, which allegedly have greater antiviral efﬁ-
cacy compared with interferon alone.19 However, the
question whether there is a correlation between HCV
infection and lymphoma development should be ad-
dressed by a properly designed trial.20
Regarding treatment, it has been suggested that
splenectomy should be the ﬁrst line of therapy.4,13–15
However, it must be noted that this assertion comes
from retrospective analyses and is not supported by
prospective, randomized, speciﬁcally designed trials.
The presenting features, therapy, and outcomes of
patients from the major retrospective series on SMZL
are compared in Table 5. It should be stressed that at
least 50% of the reported deaths were related to lym-
phoma progression or to a histology shift toward a
high-grade, non-Hodgkin lymphoma.14–17,21
Purine analogues have been tested in a few small
series of SMZL/SLVL. Fludarabine reportedly has pro-
duced a clinical response in 4 patients with recurrent
disease, including 2 durable responses, and in 5 of 10
patients in another series. Some degree of activity also
has been shown for cladribine:  50% of pretreated
patients responded to the treatment, and 2 patients
obtained a molecular complete response.3
Our experience with pentostatin, as reported in
the current series, also was promising, with a 79% ORR
and a long-lasting CR achieved in 14 patients. Ritux-
imab has been employed both alone and in combina-
tion with chemotherapy consisting of ﬂudarabine, cy-
clophosphamide, and vincristine.22–24 It is worth
noting that there were no episodes of disease recur-
rence in the complete responders after a median fol-
low-up of 10 months.22
The current experience conﬁrms that up to 20% of
patients have only splenomegaly and/or minor mod-
iﬁcations of the PB count and can be monitored safely
with a watch-and-see policy. Splenectomy easily leads
to the recovery of cytopenias both if it is undergone at
the time of presentation and if it is undergone later in
the course of the disease, and it allows for an unequiv-
ocal diagnosis. In addition, pentostatine may induce
objective responses in approximately two-thirds of pa-
tients.
In conclusion SMZL  VL is an indolent lympho-
proliferative disease that allows a long survival with up
to two-thirds of patients alive 5 years after diagnosis.
In our experience, a wise combination of morphologic
and immunophenotypic evaluation of the PB, along
with bone marrow examination, can lead to the cor-
rect diagnosis. Although it is effective in ameliorating
blood cell counts and abdominal discomfort, splenec-
tomy may induce worsening of bone marrow inﬁltra-
tion.25 Therefore, a conservative approach seems pref-
FIGURE 3. Overall survival for 57 pa-
tients who had splenic marginal zone
lymphoma/splenic lymphoma with vil-
lous lymphocytes.
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erable, and we suggest postponing splenectomy until
the disease progresses. However, the questions re-
garding the prognostic stratiﬁcation and the best ther-
apeutic strategy remain unanswered and need to be
addressed in properly designed, prospective trials.
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